Divis Laboratories
BSE: 532488 | NSE: DIVISLAB | ISIN: INE361B01024 | SECTOR: Biotechnology & DrugsOpen
3,650.00High
3,678.45Low
3,603.35Prev Close
3,638.40P/E
-Median P/E
-P/B
-Median P/B
-Market Cap
-Volume
5.23KVol. (20 day Avg.)
0PEG
-Div.Yield
-Bid
3,610.35Ask
-
Key Metrics
- Mkt. Cap.
Volatility %
Market Sentiment
- Neutral
Beta -
Genie Says
Influencer Count
42Peer Comparison
- Price Comparison
- Ratios Comparison
Company | Latest Price Change (% Chg) | 52 Week High | 52 Week Low | Market Cap. (Cr) |
---|
Events
- Dividends
- Bonus
- Splits
- Rights
- Board Meetings
- Annual General Meetings
Simple Moving Averages
Days | BSE | NSE |
---|
Divis Laboratories is trading higher than 5 day, 20 day, 100 day and 200 day moving averages.
News
Company Description
- Large Cap
- Automobiles
BSE
532488NSE
DIVISLABISIN
INE361B01024
Divi's Laboratories Limited is an India-based company, which is engaged in manufacturing and sale of active pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients with predominance in exports. The Company’s products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromethorphan HBr, Gabapentin, Iopamidol, Iohexol, Irbesartan, Lacosamide, Levetiracetam, Levodopa, Losartan, Nabumetone, Naproxen, Naproxen Sodium, Olmesartan Medoxomil, Pregabalin, Ticagrelor, Triprolidine HCl, Valacyclovir HCl, Valsartan, Venlafaxine HCl and Vigabatrin. The Company’s subsidiaries include Divi’s Laboratories USA, Inc., (Divi’s USA) and Divi’s Laboratories Europe AG (Divi’s Europe).
Company Officers
Kiran Divi
Chief Executive Officer, Whole-time DirectorL. Kishore Babu
Chief Financial OfficerM. Satish Choudhury
Chief Compliance Officer, Company SecretaryMurali Divi
Managing Director, Executive DirectorMadhusudana Divi
Whole-Time Director (Projects)Nilima Divi
Whole-Time DirectorN. Ramana
Executive Director